Interventional Oncology Market by Product (Radiofrequency, microwave, embolization, guidewires), Procedure (Thermal, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis), Enduser (Hospital, ASC) – Global Forecast to 2026 The global interventional oncology market size is projected to reach USD 2.9 billion by 2026 from USD 1.9 billion in 2020, at a CAGR of 6.8%.
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=2029743
An excellent Interventional Oncology Market research report covers the systematic and comprehensive market research study, to provide the facts and figures allied with any subject in the field of marketing. With the specific and state-of-the-art information presented in this industry report, businesses can be aware of the types of consumers, consumer’s demands and preferences, their perspectives about the product, their buying intentions, their response to a particular product, and their varying tastes about the specific product already existing in the industry. Quality and transparency is strictly maintained while carrying out research studies to offer an exceptional market research report for a specific niche.
The major players operating in the interventional oncology market are Medtronic (Ireland), Boston Scientific (US), BD (US), Terumo (Japan), Merit Medical (US), AngioDynamics (US), J&J (US), Teleflex (US), Cook Medical (US), HealthTronics (US), MedWaves (US), Sanarus (US), IMBiotechnologies (Canada), Trod Medical (US), IceCure Medical (Israel), Mermaid Medicals (Denmark), Interface Biomaterials BV (Netherlands), Guerbet (France), ABK Biomedical (Canada), Shape Memory Medical (US), Endo Shape (US), Monteris Medical (US), Instylla (US), Trisalus Lifesciences (US), Profound Medical Corp (Canada), Sirtex (US), Accuray (US), Baylis Medical (Canada), and ALPINION MEDICAL SYSTEMS (South Korea).
Interventional Oncology Market research report provides an analytical measurement of the main challenges faced by the business currently and in the upcoming years. This market report also offers a profound overview of product specification, technology, product type, and production analysis by taking into account the most important factors such as revenue, cost, and gross margin. Proficient capabilities and excellent resources in research, data collection, development, consulting, evaluation, compliance, and regulatory services come together to generate this world-class market research report. This Interventional Oncology Market report is especially designed by keeping in mind the customer requirements which will ultimately assist them in boosting their return on investment (ROI).
Factors such as the technological advancements in the market are propelling the growth of the interventional oncology market. Additionally, rising cases of surgeries, investments from both private and public sectors are having affect in the growth of interventional oncology market. However, unfavorable reimbursement scenarios in some countries is hampering the growth of this market.
The recent COVID-19 global pandemic has also impacted the interventional oncology market. Demand from the main end-users has declined as key regions and countries have imposed social distancing rules and lockdowns. This impact is expected to be short-term, and no adverse effects are to be foreseen after the market gradually reopens.
“The embolization devices segment to witness the highest share in interventional oncology market, by product, during the forecast period.”
In 2020, embolization devices accounted for a share of the interventional oncology market. Embolization devices include non-radioactive embolic agents and radioembolic agents. Although these devices are primarily employed to treat hepatocellular carcinoma, their use has been widely extended to various other forms of cancer. These devices are used when tumors cannot be treated using ablation techniques and in cases where the tumor size is large. They are also used in palliative procedures and as a pre-operative procedure to improve the outcome of liver resection.
Embolic agents include radioembolic agents and non-radioactive embolic agents. Non-radioactive embolic agents include gelatin foam, tris-acryl gelatin microspheres, and polyvinyl alcohol (PVA). Gelatin foam is a non-radioactive embolic agent and is considered a temporary embolic agent whose effect is relatively shorter. Other non-radioactive embolic agents are considered permanent agents whose effects are seen for a longer period.
“The liver cancer accounted for the largest share of the interventional oncology market, by application, in 2020.”
Liver cancer accounted for the largest share of the interventional oncology market in 2020. Interventional oncology plays a crucial role in treating liver cancer, as removing the tumor with surgery may not leave the tissue healthy enough for effective liver functioning. Thus, primary liver tumors or liver tumors resulting from metastatic cancers can effectively be treated using interventional oncology procedures. Owing to this, more than half of all treatments for primary and metastatic liver cancer are conducted using interventional oncology.
The large share of this segment can be attributed to factors such as rising cases of liver cancer across the globe and growing initiatives/research activities to develop advanced liver cancer therapies using interventional oncology. In addition, initiatives in the form of grants and funding for the development of advanced therapies using interventional oncology also fuel market growth.
“The Hospitals & diagnostic centers segment accounted for the largest share of the interventional oncology market, by end users, in 2020”
Hospitals & diagnostic centers accounted for the largest share of the interventional oncology market in 2020. The availability of state-of-the-art facilities for treating disorders and injuries and trained personnel has ensured a steady demand for hospital-based care. The inflow of patients is considerably higher in hospitals than in other healthcare settings, which is another key driver for market growth.
Hospitals routinely conduct a wide range of surgical procedures, and most of these surgeries are performed in hospital in-patient settings. Growth in this segment is primarily attributed to the growing number of minimally invasive surgeries and electrosurgery procedures performed in hospitals and the adoption of robotic surgery.
“The Asia Pacific market to grow at the highest CAGR during the forecast period.”
The interventional oncology market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Government efforts to increased funding , supportive regulations for the development and commercialization of advanced interventional oncology products, rising healthcare expenditure, increasing number of hospitals and clinics in India and China, expanding research base across India, China, and Japan, and the increasing incidence of surgeries are the major factors driving the growth of the APAC interventional oncology market.
Breakdown of supply-side primary interviews:
- By Company Type: Tier 1: 48%, Tier 2: 36%, and Tier 3: 16%
- By Designation: C-level: 10%, D-level: 14%, and Others: 76%
- By Region: North America: 45%, Europe: 24%, APAC: 20%, Latin America: 7%, and the Middle East & Africa: 4%
This report studies the interventional oncology market based on the product, procedure, cancer type, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the interventional oncology market, and high-growth regions and their drivers, restraints, opportunities, and challenges. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.
For More Information or Query or Customization Before Buying, Visit @ https://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=2029743
Table Of Contents
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope
1.3.3 Years Considered For The Study
1.6 Summary Of Changes
2 Research Methodology
2.1 Research Data
Figure 1 Interventional Oncology Market: Research Methodology Steps
Figure 2 Research Design
2.1.1 Secondary Data
220.127.116.11 Key Data From Secondary Sources
2.1.2 Primary Data
Figure 3 Breakdown Of Primaries: Global Interventional Oncology Market
Figure 4 Research Methodology: Hypothesis Building
2.2 Market Size Estimation
2.2.1 Product-Based Market Estimation
Figure 5 Interventional Oncology Market Size Estimation: Bottom-Up Approach
Figure 6 Interventional Oncology Market Size Estimation: Top-Down Approach
2.2.2 Primary Research Validation
2.3 Market Breakdown And Data Triangulation
Figure 7 Data Triangulation Methodology
2.4 Research Limitations
3 Executive Summary
Figure 8 Interventional Oncology Market, By Product, 2020 Vs. 2026 (Usd Million)
Figure 9 Interventional Oncology Market Share, By Procedure, 2020
Figure 10 Interventional Oncology Market, By Cancer Type, 2020 Vs. 2026 (Usd Million)
Figure 11 Interventional Oncology Market, By End User, 2020 Vs. 2026 (Usd Million)
Figure 12 Geographical Snapshot Of The Interventional Oncology Market
4 Premium Insights
4.1 Interventional Oncology Market Overview
Figure 13 Rising Preference For Minimally Invasive Procedures Is Driving The Growth Of The Interventional Oncology Market
4.2 Interventional Oncology Market, By Product
Figure 14 Embolization Devices To Account For The Largest Share Of The Market During The Forecast Period
4.3 Asia Pacific: Interventional Oncology Market, By Product (2020)
Figure 15 Embolization Devices Accounted For The Largest Share Of The Asia Pacific Market In 2020
4.4 Europe: Interventional Oncology Market, By Cancer Type (2020)
Figure 16 Liver Cancer Commanded The Largest Share Of The European Interventional Oncology Market In 2020
4.5 Interventional Oncology Market, By End User, 2020 Vs. 2026 (Usd Million)
Figure 17 Hospitals To Register The Highest Growth In The Forecast Period
4.6 Geographical Snapshot Of The Interventional Oncology Market
Figure 18 Asia Pacific To Register The Highest Cagr In The Interventional Oncology Market During The Forecast Period
5 Market Overview
5.2 Market Dynamics
Figure 19 Interventional Oncology Market: Drivers, Restraints, Opportunities, And Challenges
18.104.22.168 Rising Patient Preference For Minimally Invasive Procedures
22.214.171.124 Expansion Of The Target Patient Population
126.96.36.199 Increasing Public-Private Funding And Government Support For Interventional Oncology
188.8.131.52 Technological Advancements In Interventional Oncology
184.108.40.206 Dearth Of Well-Trained And Skilled Radiologists And Oncologists
220.127.116.11 Unfavorable Regulations
18.104.22.168 Emerging Economies Offer High Growth Potential
22.214.171.124 Rising Awareness About The Benefits Of Interventional Oncology
126.96.36.199 Limited Clinical Data To Support Therapeutic Efficacy
188.8.131.52 Strong Market Positioning Of Alternative Therapies
5.3 Market Trends
5.3.1 Personalized Or Precision Interventional Oncology
5.4 Regulatory Scenario
Table 1 Japan: Medical Device Classification Under Pmda
5.5 Ecosystem Coverage
5.6 Value Chain Analysis
5.7 Pricing Analysis
Get Direct Order of this Report @ https://www.reportsnreports.com/purchase.aspx?name=2029743https://jumbonews.co.uk/